What is Rapid Micro Biosystems, Inc.'s earnings per share (EPS)?

Rapid Micro Biosystems, Inc. (RPID) reported diluted earnings per share of $-1.05 for fiscal year 2025. This represents a 2.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rapid Micro Biosystems, Inc. Financials

RPID

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Rapid Micro Biosystems, Inc. (RPID) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RPID FY2025 2026-05-15

Sales growth is shrinking burn intensity, but the business still relies on external capital to preserve liquidity.

FY2025 delivered the highest revenue in this dataset at $33.6M and a -95.0% free-cash-flow margin, so each new sales dollar is carrying less loss than in prior years even though cash generation remains negative. But liquidity improved through financing, not operations: long-term debt appeared at $18.9M and financing cash flow was $19.8M, meaning the cash cushion was rebuilt externally.

Operating expense load still sits above commercial scale; SG&A plus R&D reached $36.4M against revenue of $33.6M, so better sales are narrowing losses without yet covering the fixed cost base. This is not a capital-spending story; capex was only $850K versus depreciation of $3.3M, which points to burn coming mainly from the operating model rather than expansion equipment.

Working capital is inventory-heavy: inventory ended FY2025 at $17.6M while receivables were just $3.1M, so cash is tied up more in stocked systems than in slow-paying customers. That makes a 3.3x current ratio less comforting than it looks, because current assets include a large pile of product that is harder to turn into spendable cash quickly.

Financial Health Signals

Financial Health Score 45/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Rapid Micro Biosystems, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-9.48

Rapid Micro Biosystems, Inc. scores -9.48, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($86.7M) relative to total liabilities ($41.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Rapid Micro Biosystems, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.66x

For every $1 of reported earnings, Rapid Micro Biosystems, Inc. generates $0.66 in operating cash flow (-$31.1M OCF vs -$47.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-43.5x

Rapid Micro Biosystems, Inc. earns $-43.5 in operating income for every $1 of interest expense (-$47.4M vs $1.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$33.6M

YoY+19.7%

5Y CAGR+15.9%

Rapid Micro Biosystems, Inc. generated $33.6M in revenue in fiscal year 2025. This represents an increase of 19.7% from the prior year.

EBITDA

-$44.1M

YoY+5.2%

Rapid Micro Biosystems, Inc.'s EBITDA was -$44.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 5.2% from the prior year.

Net Income

-$47.1M

YoY-0.5%

Rapid Micro Biosystems, Inc. reported -$47.1M in net income in fiscal year 2025. This represents a decrease of 0.5% from the prior year.

EPS (Diluted)

$-1.05

YoY+2.8%

Rapid Micro Biosystems, Inc. earned $-1.05 per diluted share (EPS) in fiscal year 2025. This represents an increase of 2.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$31.9M

YoY+29.9%

Rapid Micro Biosystems, Inc. generated -$31.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 29.9% from the prior year.

Cash & Debt

$20.0M

YoY+18.4%

5Y CAGR-7.8%

Rapid Micro Biosystems, Inc. held $20.0M in cash against $18.9M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

-141.1%

YoY+36.9pp

5Y CAGR+48.9pp

Rapid Micro Biosystems, Inc.'s operating margin was -141.1% in fiscal year 2025, reflecting core business profitability. This is up 36.9 percentage points from the prior year.

Net Margin

-140.3%

YoY+26.9pp

5Y CAGR+90.3pp

Rapid Micro Biosystems, Inc.'s net profit margin was -140.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 26.9 percentage points from the prior year.

Return on Equity

-141.9%

YoY-79.7pp

Rapid Micro Biosystems, Inc.'s ROE was -141.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 79.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$13.6M

YoY-6.8%

5Y CAGR+15.8%

Rapid Micro Biosystems, Inc. invested $13.6M in research and development in fiscal year 2025. This represents a decrease of 6.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$850K

YoY-37.7%

5Y CAGR+4.3%

Rapid Micro Biosystems, Inc. invested $850K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 37.7% from the prior year.

RPID Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$33.6M+19.7%	$28.1M+24.6%	$22.5M+31.4%	$17.1M-26.3%	$23.2M+44.5%	$16.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$13.6M-6.8%	$14.6M+13.9%	$12.8M-0.4%	$12.9M+31.5%	$9.8M+49.8%	$6.5M
SG&A Expenses	$22.8M+3.7%	$21.9M-12.0%	$24.9M-7.0%	$26.8M+49.9%	$17.9M+79.4%	$10.0M
Operating Income	-$47.4M+5.1%	-$49.9M+11.7%	-$56.6M+10.5%	-$63.2M-33.8%	-$47.2M-54.7%	-$30.5M
Interest Expense	$1.1M+2625.0%	$40K-99.0%	$4.2M+136.8%	$1.8M-32.9%	$2.6M-23.1%	$3.4M
Income Tax	$40K+81.8%	$22K-29.0%	$31K+105.4%	-$576K-733.0%	$91K-32.1%	$134K
Net Income	-$47.1M-0.5%	-$46.9M+10.6%	-$52.5M+13.7%	-$60.8M+17.3%	-$73.5M-98.3%	-$37.1M
EPS (Diluted)	$-1.05+2.8%	$-1.08+11.5%	$-1.22+14.7%	$-1.43+63.7%	$-3.94+96.9%	$-126.11

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$8.0M-29.1%	$11.3M+43.9%	$7.8M+7.9%	$7.3M+0.8%	$7.2M-12.3%	$8.2M+8.1%	$7.6M+14.9%	$6.6M
Cost of Revenue	$7.6M	N/A	N/A	N/A	$6.8M	N/A	N/A	N/A
Gross Profit	$371K	N/A	N/A	N/A	$404K	N/A	N/A	N/A
R&D Expenses	$3.4M+4.3%	$3.2M-8.8%	$3.5M+9.3%	$3.2M-10.9%	$3.6M+6.5%	$3.4M-5.7%	$3.6M-3.6%	$3.7M
SG&A Expenses	$7.4M+39.3%	$5.3M-5.4%	$5.6M-7.2%	$6.1M+6.8%	$5.7M+17.9%	$4.8M-15.0%	$5.7M-2.4%	$5.8M
Operating Income	-$13.9M-13.4%	-$12.2M-7.4%	-$11.4M+6.4%	-$12.1M-4.2%	-$11.7M-14.0%	-$10.2M+15.0%	-$12.0M+10.0%	-$13.4M
Interest Expense	$639K	N/A	$393K	N/A	$12K	N/A	$11K	N/A
Income Tax	$8K-42.9%	$14K+75.0%	$8K-27.3%	$11K+57.1%	$7K+177.8%	-$9K-169.2%	$13K-13.3%	$15K
Net Income	-$14.3M-14.2%	-$12.5M-8.6%	-$11.5M+3.0%	-$11.9M-5.3%	-$11.3M-16.5%	-$9.7M+14.6%	-$11.3M+10.0%	-$12.6M
EPS (Diluted)	$-0.31	N/A	$-0.26+3.7%	$-0.27-3.8%	$-0.26	N/A	$-0.26+10.3%	$-0.29

RPID Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$74.9M-23.8%	$98.2M-31.6%	$143.5M-24.8%	$190.7M-20.9%	$241.2M+244.5%	$70.0M
Current Assets	$61.2M-24.4%	$80.9M-32.8%	$120.4M-13.1%	$138.6M-36.5%	$218.1M+251.0%	$62.1M
Cash & Equivalents	$20.0M+18.4%	$16.9M-30.4%	$24.3M-10.3%	$27.1M-84.8%	$178.4M+493.1%	$30.1M
Inventory	$17.6M-12.9%	$20.2M+1.2%	$20.0M-5.8%	$21.2M+35.2%	$15.7M+74.8%	$9.0M
Accounts Receivable	$3.1M-58.3%	$7.5M+35.9%	$5.5M+3.0%	$5.4M+7.3%	$5.0M+0.3%	$5.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$41.6M+82.5%	$22.8M-10.4%	$25.5M-3.8%	$26.5M+31.2%	$20.2M-89.8%	$197.0M
Current Liabilities	$18.5M+5.2%	$17.6M-7.5%	$19.0M-0.3%	$19.1M+4.9%	$18.2M+16.9%	$15.5M
Long-Term Debt	$18.9M	$0	N/A	$0	$0-100.0%	$24.8M
Total Equity	$33.2M-55.9%	$75.4M-36.1%	$118.0M-28.1%	$164.2M-25.7%	$221.0M+274.0%	-$127.0M
Retained Earnings	-$522.4M-9.9%	-$475.3M-10.9%	-$428.4M-14.0%	-$375.9M-19.3%	-$315.1M-30.4%	-$241.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$62.4M-16.7%	$74.9M-11.3%	$84.4M+11.7%	$75.6M-11.5%	$85.4M-13.0%	$98.2M-7.3%	$105.8M-9.6%	$117.1M
Current Assets	$49.2M-19.5%	$61.2M-12.6%	$70.0M+16.3%	$60.1M-13.1%	$69.2M-14.5%	$80.9M-8.0%	$87.9M-10.5%	$98.2M
Cash & Equivalents	$13.8M-31.0%	$20.0M+5.7%	$18.9M+3.3%	$18.3M-3.0%	$18.9M+11.8%	$16.9M-23.3%	$22.0M-40.6%	$37.1M
Inventory	$17.4M-0.8%	$17.6M-16.5%	$21.1M+2.5%	$20.6M-0.8%	$20.7M+2.6%	$20.2M-5.0%	$21.3M-0.8%	$21.4M
Accounts Receivable	$6.4M+103.2%	$3.1M-42.3%	$5.4M-10.2%	$6.0M+33.8%	$4.5M-39.9%	$7.5M+101.0%	$3.7M-25.4%	$5.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$42.0M+0.8%	$41.6M+3.9%	$40.1M+90.5%	$21.0M+5.5%	$19.9M-12.6%	$22.8M+6.3%	$21.5M-4.6%	$22.5M
Current Liabilities	$19.1M+3.4%	$18.5M+11.7%	$16.5M+0.9%	$16.4M+9.4%	$15.0M-14.6%	$17.6M+10.3%	$15.9M-4.1%	$16.6M
Long-Term Debt	$19.1M+0.8%	$18.9M+0.4%	$18.8M	N/A	N/A	$0	N/A	N/A
Total Equity	$20.4M-38.6%	$33.2M-25.1%	$44.3M-18.7%	$54.5M-16.7%	$65.5M-13.1%	$75.4M-10.7%	$84.4M-10.8%	$94.6M
Retained Earnings	-$536.7M-2.7%	-$522.4M-2.5%	-$509.9M-2.3%	-$498.4M-2.4%	-$486.5M-2.4%	-$475.3M-2.1%	-$465.6M-2.5%	-$454.3M

RPID Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$31.1M+29.6%	-$44.2M+2.1%	-$45.1M+23.0%	-$58.5M-6.5%	-$55.0M-77.3%	-$31.0M
Capital Expenditures	$850K-37.7%	$1.4M-26.0%	$1.8M-72.6%	$6.7M+109.5%	$3.2M+366.2%	$690K
Free Cash Flow	-$31.9M+29.9%	-$45.5M+3.0%	-$46.9M+28.1%	-$65.3M-12.2%	-$58.2M-83.6%	-$31.7M
Investing Cash Flow	$14.3M-60.9%	$36.7M-13.0%	$42.2M+145.1%	-$93.5M-603.4%	-$13.3M+15.2%	-$15.7M
Financing Cash Flow	$19.8M+9639.4%	$203K+36.2%	$149K-78.5%	$693K-99.7%	$216.7M+237.4%	$64.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$15.1M-363.9%	-$3.2M+64.1%	-$9.1M+6.7%	-$9.7M-7.0%	-$9.1M+8.5%	-$9.9M-15.2%	-$8.6M+15.0%	-$10.1M
Capital Expenditures	$394K+328.3%	$92K+26.0%	$73K-80.1%	$366K+14.7%	$319K+225.5%	$98K-56.1%	$223K-51.4%	$459K
Free Cash Flow	-$15.5M-362.9%	-$3.3M+63.4%	-$9.1M+9.4%	-$10.1M-7.3%	-$9.4M+6.2%	-$10.0M-13.4%	-$8.8M+16.6%	-$10.6M
Investing Cash Flow	$8.6M+121.1%	$3.9M+140.6%	-$9.6M-202.6%	$9.3M-12.5%	$10.7M+119.6%	$4.9M+174.4%	-$6.5M-126.3%	$24.8M
Financing Cash Flow	$247K-44.2%	$443K-97.7%	$19.2M+6558.7%	-$298K-178.6%	$379K+6416.7%	-$6K-109.8%	$61K+710.0%	-$10K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RPID Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-141.1%+36.9pp	-178.0%+73.2pp	-251.2%+117.8pp	-369.0%-165.7pp	-203.3%-13.4pp	-190.0%
Net Margin	-140.3%+26.9pp	-167.2%+65.8pp	-233.0%+121.9pp	-354.9%-38.4pp	-316.5%-85.9pp	-230.6%
Return on Equity	-141.9%-79.7pp	-62.2%-17.8pp	-44.5%-7.4pp	-37.0%-3.8pp	-33.3%	N/A
Return on Assets	-62.9%-15.2pp	-47.8%-11.2pp	-36.6%-4.7pp	-31.9%-1.4pp	-30.5%+22.5pp	-53.0%
Current Ratio	3.31-1.3	4.61-1.7	6.34-0.9	7.27-4.7	12.01+8.0	4.00
Debt-to-Equity	0.57+0.6	0.00-0.2	0.22+0.2	0.000.0	0.00+0.2	-0.20
FCF Margin	-95.0%+67.3pp	-162.3%+46.1pp	-208.4%+172.7pp	-381.1%-130.6pp	-250.4%-53.3pp	-197.1%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	4.6%	N/A	N/A	N/A	5.6%	N/A	N/A	N/A
Operating Margin	-173.1%-64.9pp	-108.2%+36.9pp	-145.1%+22.2pp	-167.3%-5.4pp	-161.8%-37.4pp	-124.5%+33.9pp	-158.3%+43.8pp	-202.2%
Net Margin	-178.4%-67.6pp	-110.8%+36.0pp	-146.8%+16.5pp	-163.3%-7.0pp	-156.3%-38.7pp	-117.6%+31.3pp	-148.9%+41.1pp	-190.1%
Return on Equity	-70.0%-32.3pp	-37.6%-11.7pp	-25.9%-4.2pp	-21.7%-4.5pp	-17.2%-4.4pp	-12.8%+0.6pp	-13.4%-0.1pp	-13.3%
Return on Assets	-22.9%-6.2pp	-16.7%-3.1pp	-13.6%+2.1pp	-15.7%-2.5pp	-13.2%-3.3pp	-9.8%+0.8pp	-10.7%+0.0pp	-10.7%
Current Ratio	2.57-0.7	3.31-0.9	4.23+0.6	3.67-0.9	4.610.0	4.61-0.9	5.52-0.4	5.92
Debt-to-Equity	0.93+0.4	0.57+0.1	0.42+0.0	0.39+0.1	0.30+0.3	0.00-0.3	0.25+0.0	0.24
FCF Margin	-193.1%-163.5pp	-29.6%+86.8pp	-116.4%+22.2pp	-138.6%-8.4pp	-130.2%-8.5pp	-121.8%-5.7pp	-116.0%+43.8pp	-159.8%

Similar Companies

Owlet Inc OWLT

$171.8M

Profound Med Corp PROF

$266.4M

Avita Medical Inc RCEL

$135.7M

Sera Prognostics, Inc. SERA

$80.7M

Lensar Inc LNSR

$72.8M

Frequently Asked Questions

What is Rapid Micro Biosystems, Inc.'s annual revenue?

Rapid Micro Biosystems, Inc. (RPID) reported $33.6M in total revenue for fiscal year 2025. This represents a 19.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Rapid Micro Biosystems, Inc.'s revenue growing?

Rapid Micro Biosystems, Inc. (RPID) revenue grew by 19.7% year-over-year, from $28.1M to $33.6M in fiscal year 2025.

Is Rapid Micro Biosystems, Inc. profitable?

No, Rapid Micro Biosystems, Inc. (RPID) reported a net income of -$47.1M in fiscal year 2025, with a net profit margin of -140.3%.

What is Rapid Micro Biosystems, Inc.'s EBITDA?

Rapid Micro Biosystems, Inc. (RPID) had EBITDA of -$44.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Rapid Micro Biosystems, Inc. have?

As of fiscal year 2025, Rapid Micro Biosystems, Inc. (RPID) had $20.0M in cash and equivalents against $18.9M in long-term debt.

What is Rapid Micro Biosystems, Inc.'s operating margin?

Rapid Micro Biosystems, Inc. (RPID) had an operating margin of -141.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Rapid Micro Biosystems, Inc.'s net profit margin?

Rapid Micro Biosystems, Inc. (RPID) had a net profit margin of -140.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Rapid Micro Biosystems, Inc.'s return on equity (ROE)?

Rapid Micro Biosystems, Inc. (RPID) has a return on equity of -141.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rapid Micro Biosystems, Inc.'s free cash flow?

Rapid Micro Biosystems, Inc. (RPID) generated -$31.9M in free cash flow during fiscal year 2025. This represents a 29.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Rapid Micro Biosystems, Inc.'s operating cash flow?

Rapid Micro Biosystems, Inc. (RPID) generated -$31.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Rapid Micro Biosystems, Inc.'s total assets?

Rapid Micro Biosystems, Inc. (RPID) had $74.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Rapid Micro Biosystems, Inc.'s capital expenditures?

Rapid Micro Biosystems, Inc. (RPID) invested $850K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Rapid Micro Biosystems, Inc. spend on research and development?

Rapid Micro Biosystems, Inc. (RPID) invested $13.6M in research and development during fiscal year 2025.

What is Rapid Micro Biosystems, Inc.'s current ratio?

Rapid Micro Biosystems, Inc. (RPID) had a current ratio of 3.31 as of fiscal year 2025, which is generally considered healthy.

What is Rapid Micro Biosystems, Inc.'s debt-to-equity ratio?

Rapid Micro Biosystems, Inc. (RPID) had a debt-to-equity ratio of 0.57 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rapid Micro Biosystems, Inc.'s return on assets (ROA)?

Rapid Micro Biosystems, Inc. (RPID) had a return on assets of -62.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rapid Micro Biosystems, Inc.'s cash runway?

Based on fiscal year 2025 data, Rapid Micro Biosystems, Inc. (RPID) had $20.0M in cash against an annual operating cash burn of $31.1M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Rapid Micro Biosystems, Inc.'s Altman Z-Score?

Rapid Micro Biosystems, Inc. (RPID) has an Altman Z-Score of -9.48, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Rapid Micro Biosystems, Inc.'s Piotroski F-Score?

Rapid Micro Biosystems, Inc. (RPID) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rapid Micro Biosystems, Inc.'s earnings high quality?

Rapid Micro Biosystems, Inc. (RPID) has an earnings quality ratio of 0.66x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Rapid Micro Biosystems, Inc. cover its interest payments?

Rapid Micro Biosystems, Inc. (RPID) has an interest coverage ratio of -43.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Rapid Micro Biosystems, Inc.?

Rapid Micro Biosystems, Inc. (RPID) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.